E1A, E1B double-restricted adenovirus for oncolytic gene therapy of gallbladder cancer

Cancer Research

Volumn 63, Issue 15, 2003, Pages 4434-4440

  Fukuda, Kuniaki ^a,b   Abei, Masato ^a   Ugai, Hideyo ^b   Seo, Emiko ^a,b   Wakayama, Mariko ^a,b   Murata, Takehide ^b   Todoroki, Takeshi ^a   Tanaka, Naomi ^a   Hamada, Hirofumi ^c   Yokoyama, Kazunari K ^b  

^a UNIVERSITY OF TSUKUBA   (Japan)

^b RIKEN   (Japan)

^c SAPPORO MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; E1A PROTEIN; E1B PROTEIN; RETINOBLASTOMA PROTEIN; UNCLASSIFIED DRUG; VIRUS PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL DESTRUCTION; CYTOPATHOGENIC EFFECT; E1A GENE; E1B GENE; FEMALE; GALLBLADDER CANCER; GENE; GENE THERAPY; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR XENOGRAFT; VIRUS MUTANT; VIRUS REPLICATION; WILD TYPE;

ADENOVIRIDAE; ADENOVIRUS E1A PROTEINS; ADENOVIRUS E1B PROTEINS; ANIMALS; FEMALE; GALLBLADDER NEOPLASMS; GENE THERAPY; HUMANS; MICE; MICE, INBRED BALB C; MICE, NUDE; VIRUS REPLICATION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 0041589480     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Pitt, H. A., Dooley, W. C., Yeo, C. J., and Cameron, J. L. Malignancies of the biliary tree. Curr. Probl. Surg., 32: 1-90, 1995.
2. Donohue, J. H., Stewart, A. K., and Menck, H. R. The National Cancer Data Base Report on Carcinoma of the Gallbladder, 1989-1995. Cancer (Phila.), 83: 2618-2628, 1998.
3. Schauer, R. J., Meyer, G., Baretton, G., Schildberg, F. W., and Rau, H. G. Prognostic factors and long-term results after surgery for gallbladder carcinoma: a retrospective study of 127 patients. Langenbecks Arch. Surg., 386: 110-117, 2001.
4. Kamel, D., Paakko, P., Nuorva, K., Vahakangas, K., and Soini, Y. p53 and c-erbB-2 protein expression in adenocarcinomas and epithelial dysplasias of the gallbladder. J. Pathol., 170: 67-72, 1993.
5. Hanada, K., Itoh, M., Fujii, K., Tsuchida, A., Ooishi, H., and Kajiyama, G. K-ras and p53 mutations in stage I gallbladder carcinoma with an anomalous junction of the pancreaticobiliary duct. Cancer (Phila.), 77: 452-458, 1996.
6. Caca, K., Feisthammel, J., Klee, K., Tannapeel, A., Witzigmann, H., Wittekind, C., Mossner, J., and Berr, F. Inactivation of the INK4A/ARF locus and p53 in sporadic extrahepatic bile duct cancers and bile tract cancer cell lines. Int. J. Cancer, 97: 481-488, 2002.
7. Ink4B/MTS2 gene in biliary tract cancers. Cancer Res., 55: 2756-2760, 1995.
8. INK4 protein in gallbladder. carcinomas. Clin. Cancer Res., 6: 4096-4100, 2000.
9. Nakano, K., Todo, T., Chijiiwa, K., and Tanaka, M. Therapeutic efficacy of G207, a conditionally replicating herpes simplex virus type 1 mutant, for gallbladder carcinoma in immunocompetent hamsters. Mol. Ther., 3: 431-437, 2001.
10. Ries, S., and Korn, W. M. ONYX-015: mechanism of action and clinical potential of a replication-selective adenovirus. Br. J. Cancer, 86: 5-11, 2002.
11. Kirn, D. Replication-selective oncolytic adenoviruses: virotherapy aimed at genetic targets in cancer. Oncogene, 19: 6660-6669, 2000.
12. Heise, C., and Kirn, D. H. Replication-selective adenoviruses as oncolytic agents. J. Clin. Investig., 105: 847-851, 2000.
13. Alemany, M., and Curiel, D. T. The development of conditionally replicative adenovirus for cancer therapy. Clin. Cancer Res., 6: 3395-3399, 2000.
14. McCormick, F. Interactions between adenovirus proteins and the p53 pathway: the development of ONYX-015. Semin. Cancer Biol., 10: 453-459, 2000.
15. Dix, B. R., Edwards, S. J., and Braithwaite, A. W. Does the antitumor adenovirus ONYX-015/d11520 selectively target cells defective in the p53 pathway? J. Virol., 75: 5443-5447, 2001.
16. Heise, C., Jhoannes, A. S., Williams, A., McCormick, F., Hoff, D. D. V., and Kim, D. H. ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents. Nat. Med., 3: 639-645, 1997.
17. Khuri, F. R., Nemunaitis, J., Ganly, I., Arseneau, J., Tannock, I. F., Romel, L., Gore, M., Ironside, J., MacDougall, R. H., Heise, C., Randlev, B., Gillenwater, A. M., Bruso, P., Kaye, S. B., Hong, W. K., and Kirn, D. H. A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer. Nat. Med., 6: 879-885, 2000.
18. Habib, N., Salama, H., Median, A. A. E. L. A., Anis, I. I., Aziz, R. A. A. A. A., Sarraf, C., Mitry, R., Havlik, R., Seth, P., Hartwigsen, J., Bhushan, R., Nicholls, J., and Jensen, S. Clinical trial of EIB-deleted adenovirus (dl1520) gene therapy for hepatocellular carcinoma. Cancer Gene Ther., 9: 254-259, 2002.
19. Heise, C., Hermiston, T., Johnson, L., Brooks, G., Jhoannes, A. S., Williams, A., Hawkins, L., and Kirn, D. H. An adenovirus E1A mutant that demonstrates potent and selective systemic anti-tumoral efficacy. Nat. Med., 6: 1134-1139, 2000.
20. Fueyo, J., Gomez-Manzano, C., Alemany, R., Lee, P. S. Y., McDonnell, T. J., Mitlianga, P., Shi, Y. X., Levin, V. A., and Yung, W. K. A. A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo. Oncogene, 19: 2-12, 2000.
21. Doronin, S., Toth, K., Kuppuswamy, M., Ward, P., Tollefson, A. E., and Wold, W. S. M. Tumor-specific, replication-competent adenovirus vectors overexpressing the adenovirus death protein. J. Virol., 74: 6147-6155, 2000.
22. Howe, J. A., Demers, G. W., Jhonson, D. E., Neugebauer, S. E. A., Perry, S. T., Vaillancourt, M. T., and Faha, B. Evaluation of El-mutant adenoviruses as conditionally replicating agents for cancer therapy. Mol. Ther., 2: 485-495, 2000.
23. Sherr, C. J., and McCormick, F. The Rb and p53 pathways in cancer. Cancer Cell, 2: 103-112, 2002.
24. Rothmann, T., Hengstermann, A., Whitaker, N. J., Scheffner, M., and Hausen, H. Replication of ONYX-015, a potential anticancer adenovirus, is independent of p53 status in tumor cells. J. Virol., 72: 9470-9478, 1998.
25. Goodrum, F. D., and Ornelles, D. A. p53 status does not determine outcome of E1B 55-kilodalton mutant adenovirus lytic infection. J. Virol., 72: 9479-9490, 1998.
26. Harada, J. N., and Berk, A. J. p53-independent and -dependent requirements for E1B-55K in adenovirus type 5 replication. J. Virol., 73: 5333-5344, 1999.
27. Ohashi, M., Kanai, F., Tateishi, K., Taniguchi, H., Marignani. P. A., Yoshida, Y., Shiratori, Y., Hamada, H., and Omata, M. Target gene therapy for α-fetoprotein-producing hepatocellular carcinoma by E1B55k-attenuated adenovirus. Biochem. Biophys. Res. Commun., 282: 529-535, 2001.
28. Motoi, F., Sunamura, M., Ding, L., Duda, D. G., Yoshida, Y., Zhang, W., Matsuno, S., and Hamada, H. Effective gene therapy for pancreatic cancer by cytokines mediated by restricted replication-competent adenovirus. Hum. Gene Ther., 11: 223-235, 2000.
29. Knuth, A., Gabbert, H., Dippold, W., Klein, O., Sachsse, W., Bitter-Suermann, D., Prellwitz, W., and Meyer zum Buschenfelde, K. H. Biliary adenocarcinoma. Characterisation of three new human tumor cell lines. J. Hepatol., 1: 579-596, 1985.
30. Moon, Y., Dahlberg, W. K., Yu, Y., Ohno, T., Todoroki, T., and Little, J. B. Radiosensitivity of human biliary tract cancer cells in vitro. Int. J. Oncol., 10: 545-551, 1997.
31. Shinoura, N., Yoshida, Y., Tsunoda, R., Ohashi, M., Zhang, W., Asai, A., Kirino, T., and Hamada, H. Highly augmented cytopathic effect of a fiber-mutant E1B-defective adenovirus for gene therapy of gliomas. Cancer Res., 59: 3411-3416, 1999.
32. Heise, C., Lemmon, M., and Kirn, D. Efficacy with a replication-selective adenovirus plus cisplatin-based chemotherapy: dependence on sequencing but not p53 functional status or route of administration. Clin. Cancer Res., 6: 4908-4914, 2000.
33. You, L., Yang, C. T., and Jablons, D. M. ONYX-015 works synergistically with chemotherapy in lung cancer cell lines and primary cultures freshly made from lung cancer patients. Cancer Res., 60: 1009-1013, 2000.
34. Rogulski, K. R., Wing, M. S., Paielli, D. L., Gilbert, J. D., Kim, J. H., and Freytag, S. O. Double suicide gene therapy augments the antitumor activity of a replication-competent lytic adenovirus through enhanced cytotoxicity and radiosensitization. Hum. Gene Ther., 11: 67-76, 2000.
35. Wildner, O., Blaese, R. M., and Morris, J. C. Therapy of colon cancer with oncolytic adenovirus is enhanced by the addition of herpes simplex virus-thymidine kinase. Cancer Res., 59: 410-413, 1999.
36. Ueno, N. T., Yu, D., and Hung, M. C. Chemosensitization of HER-2/neu-overexpressing human breast cancer cells to paclitaxel (Taxol) by adenovirus type 5 E1A. Oncogene, 15: 953-960, 1997.
37. Zhou, R. R., Jia, S. F., Wang, Y., Bucana, C. D., and Kleinerman, E. S. Adenovirus-E1A gene therapy enhances the in vivo sensitivity of Ewing's sarcoma to VP-16. Cancer Gene Ther., 9: 407-413, 2002.
38. ARF in tumor cells facilitates replication of the adenovirus mutant d11520 (ONYX015). Nat. Med., 6: 1128-1133, 2000.
39. Douglas, J. T., Kim, M., Sumerel, L. A., Carey, D. E., and Curiel, D. T. Efficient oncolysis by a replicating adenovirus (Ad) in vivo is critically dependent on tumor expression of primary Ad receptors. Cancer Res., 61: 813-817, 2001.
40. Nakamura, T., Sato, K., and Hamada, H. Effective gene transfer to human melanomas via integrin-targeted adenoviral vectors. Hum. Gene Ther., 13: 613-626, 2002.
41. Kashentseva, E. A., Seki, T., Cruiel, D. T., and Dmitriev, I. P. Adenovirus targenting to c-erbB-2 oncoprotein by single-chain antibody fused to trimeric form of adenovirus receptor ectodomain. Cancer Res., 62: 609-616, 2002.